The cost of treatment for lung cancer patients will be further reduced and the survival time will be longer if the domestic immune drugs are included in the medical insurance

Sindilimab is a domestic anti PD-1 monoclonal antibody, trade name: dabesu, it is jointly developed by Cinda biopharmaceutical and Lilly pharmaceutical in China. Like the imported PD-1 monoclonal antibody, it can specifically bind PD-1 molecules on the surface of T cells, thus blocking the PD-1 / PD-L1 pathway that leads to tumor immune tolerance and reactivates the anti-tumor activity of lymphocytes, so as to achieve the purpose of tumor treatment. Sindilimab is the first Chinese immunotherapy drug to be published in top journals. < / P > < p > in December 2018, sindilimab was approved for the treatment of recurrent / refractory classical Hodgkin’s lymphoma. Autologous hematopoietic stem cell transplantation and bentuximab are commonly used as the standard treatment for relapsed and refractory Hodgkin’s lymphoma in the world. However, due to the limitation of economic conditions or the inability to purchase this drug, the vast majority of patients in China can not receive the standard treatment. It should be said that dabesur offers more choices for such patients. The clinical trial of orient-1, led by Professor Shi Yuankai, Department of internal medicine, cancer hospital, medical college, showed that the effective rate of the drug was as high as 80.4%. In terms of indications for lung cancer, the State Drug Administration has officially accepted the application for the first-line treatment of lung cancer with sindilimab combined with chemotherapy, including two indications of squamous cell carcinoma and non squamous cell carcinoma. < p > < p > results of the clinical trial of cindilimab combined with libitum and platinum based chemotherapy for advanced non-small cell lung cancer at the world lung cancer conference in 2020. The median progression free survival time was 8.9 months vs. 5.0 months in the experimental group vs. the control group, and the risk of progression was reduced by 52% in the combined treatment group. Objective response rate: 51.9% vs. 29.8%, and sindilimab can make patients get remission earlier. The phase III study of cindilimab combined with gemcitabine and platinum chemotherapy in the first-line treatment of squamous non-small cell lung cancer has reached the main end point. The experimental group was treated with cindilimab, gemcitabine and platinum, while the control group was replaced with placebo. The results showed that the progression free survival of the experimental group was significantly longer than that of the control group, and there was no new safety signal. < / P > < p > in November 2019, sindilimab was included in the national medical insurance, and entered the first batch of 4 + 7 drug list, becoming the only PD-1 antibody in the medical insurance list, with the price of 2843 yuan / bottle. Compared with the similar domestic PD-1 monoclonal antibody, the price is very close to the people, but the cancer that can be reimbursed is recurrent / refractory Hodgkin’s lymphoma. We hope that sindilimab can be approved as soon as possible for lung cancer indications, so that more lung cancer patients can use this civilian immunotherapy. 2